Cargando…

The Efficacy of Bisphosphonates in Preventing Aromatase Inhibitor Induced Bone Loss for Postmenopausal Women with Early Breast Cancer: A Systematic Review and Meta-Analysis

Objectives. We aim to determine the efficacy of bisphosphonates in preventing aromatase inhibitor induced bone loss (AIBL) in postmenopausal women with early breast cancer. The secondary objective was to determine the safety of bisphosphonates. Materials and Methods. We searched electronic databases...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anagha, Pooleriveetil Padikkal, Sen, Suchandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984802/ https://www.ncbi.nlm.nih.gov/pubmed/24795759 http://dx.doi.org/10.1155/2014/625060

Ejemplares similares

Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial
por: Lomax, Anna J., et al.
Publicado: (2013)

Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy
por: Dieckmeyer, Michael, et al.
Publicado: (2019)

Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer
por: Gonnelli, Stefano, et al.
Publicado: (2008)

Bone loss and the aromatase inhibitors
por: Lester, J, et al.
Publicado: (2005)

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
por: Goss, Paul E, et al.
Publicado: (2007)

Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
por: Chen, Shanshan, et al.
Publicado: (2022)

Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole
por: Sun, Shengliang, et al.
Publicado: (2016)

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer
por: Kadakia, Kunal C., et al.
Publicado: (2016)

Protective effect of bisphosphonate on the cortical bone at key locations of the femur in aromatase inhibitor-associated bone loss: A three-dimensional cortical bone mapping study
por: Hong, Namki, et al.
Publicado: (2021)

Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer
por: Pfeiler, G, et al.
Publicado: (2013)

Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer
por: Martino, Gabriella, et al.
Publicado: (2020)

Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer
por: Chen, Han, et al.
Publicado: (2020)

Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2013)

Bone metabolism genes variation and response to bisphosphonate treatment in women with postmenopausal osteoporosis
por: Marozik, Pavel, et al.
Publicado: (2019)

Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors
por: Gibb, Fraser W, et al.
Publicado: (2019)

Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition
por: Van Poznak, Catherine
Publicado: (2010)

Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study
por: Wang, Xue, et al.
Publicado: (2020)

Sleep disturbances and restless legs syndrome in postmenopausal women with early breast cancer given adjuvant aromatase inhibitor therapy
por: Pedersini, Rebecca, et al.
Publicado: (2022)

Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions
por: Ligibel, Jennifer A, et al.
Publicado: (2005)

CORRIGENDUM to “Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study”
Publicado: (2020)

Aromatase Activity and Bone Loss in Men
por: Merlotti, Daniela, et al.
Publicado: (2011)

Role of Bisphosphonates in Postmenopausal Women with Osteoporosis to Prevent Future Fractures: A Literature Review
por: Imam, Bashir, et al.
Publicado: (2019)

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
por: Zhu, Yilin, et al.
Publicado: (2019)

Efficacy of bisphosphonate therapy on postmenopausal osteoporotic women with and without diabetes: a prospective trial
por: Kim, Jinyoung, et al.
Publicado: (2022)

Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer
por: Sakaguchi, Koichi, et al.
Publicado: (2019)

Bisphosphonates for Prevention of Bone Loss in Glucocorticoid-Treated Young People
por: Reid, Ian R.
Publicado: (2019)

Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy
por: Pedersini, Rebecca, et al.
Publicado: (2019)

Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2021)

Intravenous bisphosphonates for postmenopausal osteoporosis
por: Mottaghi, Peyman
Publicado: (2010)

Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women
por: Augoulea, A., et al.
Publicado: (2017)

Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice
por: Bock, Oliver, et al.
Publicado: (2008)

Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
por: Young, Patricia A., et al.
Publicado: (2021)

The effect of exercise training on endothelial function in postmenopausal women with breast cancer under aromatase inhibitor therapy
por: Mayr, Barbara, et al.
Publicado: (2022)

From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors
por: Vasconcelos de Matos, Leonor, et al.
Publicado: (2021)

Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
por: Hadji, Peyman, et al.
Publicado: (2017)

Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors
por: Hong, Dongsheng, et al.
Publicado: (2017)

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
por: Cairns, Junmei, et al.
Publicado: (2020)

Influence of bisphosphonate therapy on bone geometry, volumetric bone density and bone strength of femoral shaft in postmenopausal women with rheumatoid arthritis
por: Meinen, Rahel, et al.
Publicado: (2016)

Effect of Denosumab on Glucose Homeostasis in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors: A Pilot Study
por: Rossini, Alessandro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e2hslg60sl60t86d69o6l4s0ks